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EditorialFighting the bushﬁre in HCC trialsUntil recently, few options for systemic therapy have been avail-
able for hepatocellular carcinoma (HCC). However, signiﬁcant
beneﬁts have now been demonstrated for the kinase inhibitor
sorafenib [1] that have led to its approval for HCC therapy in
the palliative setting. This has dramatically increased the previ-
ously timid interest of drug companies for HCC, and indeed there
are now on their way more than 50 phase I–III clinical trials
employing more or less targeted substances. This is certainly a
positive development in the interest of HCC patients and clinical
liver cancer research. Nevertheless, for the sake of the whole
ﬁeld, we have to point out aspects that may be decisive in
whether this impact may be sustainable or just a bushﬁre ulti-
mately leading to wasteland.
According to current guidelines, HCC is the only relevant
malignant tumor that does not require mandatory histological
examination for the establishment of its speciﬁc diagnosis [2].
Consequently, the spectrum of HCCs submitted to biopsy is shift-
ing dramatically towards early, small lesions (<2 cm), that do not
provide speciﬁc diagnostic imaging features. We do not want to
address the resulting diagnostic problems that may come along
with this; instead, it is necessary to elaborate on the conse-
quences for study design and future strategies:
 Since clinical diagnosis of HCC does not require mandatory tis-
sue analysis, neither do clinical trials. Thus, clinical trials are
set-up either without histology as inclusion criterion, or
without upfront tissue availability or even retrospective tis-
sue-based biomarker analysis. This may be driven by consider-
ations regarding patient recruitment, or by the intention of
some companies to avoid narrowing down the patient pool
addressed by the drug. Even in the SHARP trial it is impossible
to answer the questions whether certain molecularly deﬁned
tumor subgroups show a better or no response to sorafenib.
 Companies’ interest in HCC is far from altruistic but is sub-
jected to competitive considerations in comparison to other
malignancies. In this context we should not forget that HCC
has worse starting conditions compared to other tumors since
study endpoint deﬁnitions and evaluations are more difﬁcult
due to confounding morbidity, such as cirrhosis. Accumulation
of failed targeted approaches (non-superiority; failed market
penetration) might rapidly cool down industries’ interest and
divert it to other cancers. Is this scenario likely? We believe,
yes. Evidence from the Phase III sunitinib trial that was
recently halted because of unwanted effects and did not show
overall signiﬁcant beneﬁt [3] indicates that targeted
approaches may fail in unspeciﬁed HCC collectives in terms
of overall survival or time to progression (TTP). In the future
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patient subgroups that respond positively and patients that
may have disadvantages by a speciﬁc therapy. This can only
be achieved by having tumor tissue in hand not only for diag-
nosis but also for biomarker assessment. In the light of many
ongoing trials and considerations about cost-beneﬁt ratios it
is unlikely that health agencies will wait long until they will
tighten regulations for approval even when signiﬁcant overall
response is demonstrated. A likely scenario is mandatory sub-
group analysis.
 Is there any valid alternative to tumor tissue? We believe not!
It is necessary to have blood/serum available, and serum mar-
ker assessment should always be attempted but the quest for
predictive serummarkers is a story of failures so far; not a sin-
gle predictive serum tumor marker has been established to
date, and many potential biomarkers may not show up in
the serum at all; building biomarker analysis solely on serum
is therefore building on sand.
 Several types of cancer research ﬁelds that are far ahead of
HCC give strong indications as to how future predictive testing
in non-resectable malignant diseases will look. In mammary
carcinoma, multiple systemic therapy options exist and
upfront tissue-based molecular testing (e.g. ER, PR, Her2) is
mandatory and guides therapeutic decision making [4]. A sim-
ilar scenario is about to develop in non-resectable non-small
cell lung cancer (NSCLC). In the future, it may/will be tested
upfront for e.g. EGFR-mutation, ELM4-ALK translocation,
ERCC1 and TS expression. Multiple therapeutic options, test-
ing logistics, and reimbursement strategies are dictating this
path and novel adaptive trial strategies [5] will further neces-
sitate it. Interestingly, drug companies holding a non-
restricted approval for targeted drugs in hand (e.g. in NSCLC)
are intending to switch to approval with upfront molecular
testing.
Therefore, upfront tissue-based molecular testing prior to
adjuvant or palliative systemic treatment is not a ﬁction but
a fact in oncology, and if we are unable to provide this modality
for HCC we will soon drop far behind in all trial priorities. Fur-
thermore, clear cut indications now exist in tumors such as
NSCLC and colon cancer that even conventional (chemo)thera-
peutic approaches should be subjected to molecular subgroup
analyses in order to adjust treatment and potentially avoid
exposure to toxic agents [6].
Thus, we are convinced, there is no way around mandatory
acquisition of HCC tissue in clinical trials (and consequently, in
subsequent routine diagnostic setting). This shift in paradigm
should happen soon; otherwise, the current positive trial constel-
lation may turn out to be just a bushﬁre. Individualized HCC ther-
apy will require deﬁning the patient subgroups that beneﬁt most
or that should be protected from therapy failure and unwanted
effects [7]. Decision against mandatory biopsy of HCC was made011 vol. 55 j 276–277
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in old times, when no differential systemic therapy was on the
horizon and, clearly, it has to be revisited urgently in the light
of upcoming diagnostic [8,9] and therapeutic options. In the
end, it is also an ethical issue to set up clinical trials in a way that
optimizes data interpretation for the sake of future patients.Conﬂict of interest
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